• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of sulfonylurea compounds on Pneumocystis carinii.

作者信息

Hughes W T, Smith-McCain B L

出版信息

J Infect Dis. 1986 May;153(5):944-7. doi: 10.1093/infdis/153.5.944.

DOI:10.1093/infdis/153.5.944
PMID:3486236
Abstract

Two sulfonylurea compounds, carbutamide and tolbutamide, were studied for efficacy against Pneumocystis carinii pneumonitis in the corticosteroid-treated rat model and compared with trimethoprim-sulfamethoxazole (TMP-SMZ). The chemical structures of these sulfonylureas are identical except that an amino group in carbutamide is replaced with a methyl group in tolbutamide. Carbutamide was totally effective in the prevention and treatment of P. carinii pneumonitis in dosages of 100 and 200 mg/kg per day. The carbutamide dosage of 50 mg/kg per day prevented the infection in 90% of animals, whereas tolbutamide in the same dosage permitted infection in 100% of animals. This study shows that carbutamide is at least as effective as TMP-SMZ in the treatment and prevention of murine P. carinii pneumonitis. The presence of an amino group in the para position on the benezene ring is a determinant for this activity.

摘要

相似文献

1
Effects of sulfonylurea compounds on Pneumocystis carinii.
J Infect Dis. 1986 May;153(5):944-7. doi: 10.1093/infdis/153.5.944.
2
Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children.甲氧苄啶-磺胺甲恶唑治疗儿童卡氏肺孢子虫肺炎
Rev Infect Dis. 1982 Mar-Apr;4(2):602-7. doi: 10.1093/clinids/4.2.602.
3
Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.预防卡氏肺孢子虫肺炎时不同剂量、给药间隔及药物的比较。
Antimicrob Agents Chemother. 1988 May;32(5):623-5. doi: 10.1128/AAC.32.5.623.
4
Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid.甲氧苄啶-磺胺甲恶唑治疗卡氏肺孢子虫肺炎的耐药性。亚叶酸的影响。
Chest. 1984 Jul;86(1):149-50. doi: 10.1378/chest.86.1.149.
5
Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.二氨基二苯砜及其他药物对鼠卡氏肺孢子虫肺炎的疗效
Antimicrob Agents Chemother. 1984 Oct;26(4):436-40. doi: 10.1128/AAC.26.4.436.
6
Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide.用4,4'-磺酰双甲酰苯胺成功治疗和预防小鼠卡氏肺孢子虫肺炎。
Antimicrob Agents Chemother. 1986 Mar;29(3):509-10. doi: 10.1128/AAC.29.3.509.
7
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.实验性卡氏肺孢子虫肺炎中的表面活性物质磷脂和灌洗磷脂酶A2
Am Rev Respir Dis. 1986 Sep;134(3):526-31. doi: 10.1164/arrd.1986.134.3.526.
8
Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii.甲氧苄啶-磺胺甲恶唑治疗成人卡氏肺孢子虫肺炎
Rev Infect Dis. 1982 Mar-Apr;4(2):608-13. doi: 10.1093/clinids/4.2.608.
9
Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.乙磺半胱氨酸戊烷脒与甲氧苄啶-磺胺甲恶唑治疗卡氏肺孢子虫肺炎的比较。
J Pediatr. 1978 Feb;92(2):285-91. doi: 10.1016/s0022-3476(78)80028-6.
10
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.磺胺类药物预防卡氏肺孢子虫肺炎的单药疗效。
Antimicrob Agents Chemother. 1996 Apr;40(4):962-5. doi: 10.1128/AAC.40.4.962.

引用本文的文献

1
Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus.运用药物流行病学研究磺脲类药物与糖尿病患者感染风险之间的相互作用。
CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):718-725. doi: 10.1002/psp4.13308. Epub 2025 Jan 28.
2
Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study.抗糖尿病药物对 COVID-19 临床结局的影响:一项全国范围内的基于人群的研究。
Endocrinol Metab (Seoul). 2024 Jun;39(3):479-488. doi: 10.3803/EnM.2023.1857. Epub 2024 Jan 29.
3
Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.
2 型糖尿病合并 COVID-19 患者的非胰岛素类抗糖尿病药物:文献评价。
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):159-167. doi: 10.1016/j.dsx.2020.12.026. Epub 2020 Dec 15.
4
Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review.评估糖尿病合并 COVID-19 患者的风险、严重程度、死亡率、血糖控制和抗糖尿病药物:叙述性综述。
Diabetes Res Clin Pract. 2020 Jul;165:108266. doi: 10.1016/j.diabres.2020.108266. Epub 2020 Jun 11.
5
Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.叶酸合成抑制剂在实验性卡氏肺孢子虫肺炎治疗中的应用
Antimicrob Agents Chemother. 1988 Jan;32(1):96-103. doi: 10.1128/AAC.32.1.96.
6
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.阳离子抗锥虫药及其他抗菌药物在实验性卡氏肺孢子虫肺炎治疗中的应用
Antimicrob Agents Chemother. 1988 Jun;32(6):896-905. doi: 10.1128/AAC.32.6.896.
7
Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.氟喹诺酮类药物用于预防小鼠卡氏肺孢子虫肺炎。
Antimicrob Agents Chemother. 1992 Feb;36(2):470-2. doi: 10.1128/AAC.36.2.470.
8
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.实验性肺孢子菌病的治疗:七年经验回顾及抗菌药物分类新系统的开发
Antimicrob Agents Chemother. 1992 Sep;36(9):1943-50. doi: 10.1128/AAC.36.9.1943.
9
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.抗叶酸、抗病毒及其他药物在卡氏肺孢子虫肺炎免疫抑制大鼠模型中的活性
Antimicrob Agents Chemother. 1992 Sep;36(9):1935-42. doi: 10.1128/AAC.36.9.1935.